Editorial: Unmet Therapeutic Needs Modern

pharmacotherapy for schizophrenia began with the introduction of chlorpromazine in 1952. About the same time principles from social psychiatry were being implemented, and the locus of care shifted away from chronic care hospitals. Empirically validated forms of psychosocial treatment have now joined drug treatment in evidence-based practice. But it has been difficult to ro-bustly alter long-term outcome.1 Current treatments ap-pear most robust in effecting psychosis,2 and there has been little progress on the aspects of schizophrenia that appear to account for poor functional outcomes. In this regard, impaired cognition and primary negative symptoms represent unmet therapeutic needs and chal-lenge the field for innovation and discovery. The National Institute of Mental Health (NIMH) has crystallized a focus on cognition in schizophrenia wit